TN2015000168A1 - Inhibiteurs de la tyrosine kinase de bruton - Google Patents

Inhibiteurs de la tyrosine kinase de bruton

Info

Publication number
TN2015000168A1
TN2015000168A1 TNP2015000168A TN2015000168A TN2015000168A1 TN 2015000168 A1 TN2015000168 A1 TN 2015000168A1 TN P2015000168 A TNP2015000168 A TN P2015000168A TN 2015000168 A TN2015000168 A TN 2015000168A TN 2015000168 A1 TN2015000168 A1 TN 2015000168A1
Authority
TN
Tunisia
Prior art keywords
tyrosine kinase
inhibitors
compounds
disclosed
conditions
Prior art date
Application number
TNP2015000168A
Other languages
English (en)
Inventor
John Robert Springer
Balekudru Devadas
Danny James Garland
Margaret Lanahan Grapperhaus
Seungil Han
Susan Landis Hockerman
Robert Owen Hughes
Eddine Saiah
Mark Edward Schnute
Shaun Raj Selness
Daniel Patrick Walker
Zhao-Kui Wan
Li Xing
Christoph Wolfgang Zapf
Michelle Ann Schmidt
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49596360&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2015000168(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of TN2015000168A1 publication Critical patent/TN2015000168A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

Il est divulgué dans le présent mémoire des composés qui forment des liaisons covalentes avec la tyrosine-kinase de Bruton (BTK) . Des procédés pour la préparation des composés sont divulgués. Il est également divulgué des compositions pharmaceutiques qui comprennent les composés. Il est divulgué des procédés d'utilisation des inhibiteurs de BTK, seuls ou en association avec d'autres agents thérapeutiques, pour le traitement de maladies ou affections auto-immunes, de maladies ou affections hétéroimmunes,d'un cancer, y compris d'un lymphome, et de maladies ou d'affections inflammatoires. (Formule I) .
TNP2015000168A 2012-11-02 2015-04-30 Inhibiteurs de la tyrosine kinase de bruton TN2015000168A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261721920P 2012-11-02 2012-11-02
US201361772028P 2013-03-04 2013-03-04
PCT/IB2013/059846 WO2014068527A1 (fr) 2012-11-02 2013-11-01 Inhibiteurs de la tyrosine kinase de bruton

Publications (1)

Publication Number Publication Date
TN2015000168A1 true TN2015000168A1 (fr) 2016-10-03

Family

ID=49596360

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2015000168A TN2015000168A1 (fr) 2012-11-02 2015-04-30 Inhibiteurs de la tyrosine kinase de bruton

Country Status (27)

Country Link
US (4) US20150291554A1 (fr)
EP (1) EP2914586B1 (fr)
JP (1) JP6178861B2 (fr)
KR (1) KR101668574B1 (fr)
CN (1) CN105008344B (fr)
AP (1) AP2015008381A0 (fr)
AU (1) AU2013340345B2 (fr)
BR (1) BR112015009624A2 (fr)
CA (1) CA2888960C (fr)
CL (1) CL2015001168A1 (fr)
CO (1) CO7350624A2 (fr)
CR (1) CR20150228A (fr)
DO (1) DOP2015000100A (fr)
EA (1) EA201500393A1 (fr)
ES (1) ES2625944T3 (fr)
GE (1) GEP201606597B (fr)
HK (1) HK1211293A1 (fr)
IL (1) IL238571A0 (fr)
MD (1) MD20150035A2 (fr)
MX (1) MX2015005422A (fr)
NI (1) NI201500059A (fr)
PE (1) PE20151070A1 (fr)
PH (1) PH12015500940A1 (fr)
SG (1) SG11201502893WA (fr)
TN (1) TN2015000168A1 (fr)
TW (1) TWI518080B (fr)
WO (1) WO2014068527A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882741B1 (fr) 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
KR102203990B1 (ko) 2012-09-10 2021-01-18 프린시피아 바이오파마, 인코퍼레이티드 키나제 저해제로서의 피라졸로피리미딘 화합물
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
US8895750B2 (en) 2013-03-14 2014-11-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
WO2014152114A1 (fr) 2013-03-15 2014-09-25 Boehringer Ingelheim International Gmbh Composés hétéroaromatiques en tant qu'inhibiteurs de btk
MY194905A (en) * 2013-03-15 2022-12-22 Janssen Pharmaceutica Nv Processes and Intermediates for Preparing a Medicament
RS60847B1 (sr) * 2013-08-19 2020-10-30 Taris Biomedical Llc Uređaji za davanje više jedinica leka
EP3052476B1 (fr) 2013-09-30 2020-07-15 Guangzhou InnoCare Pharma Tech Co., Ltd. Inhibiteurs de nicotinimide substitués de btk et leur préparation et utilisation dans le traitement du cancer, d'inflammations et des maladies auto-immunes
WO2015116485A1 (fr) 2014-01-29 2015-08-06 Boehringer Ingelheim International Gmbh Composés de pyrazole utilisés en tant qu'inhibiteurs de btk
PT3107544T (pt) 2014-02-21 2021-01-05 Principia Biopharma Inc Sais e forma sólida de um inibidor de btk
WO2015185998A2 (fr) * 2014-04-11 2015-12-10 Acerta Pharma B.V. Procédés de blocage de la voie de signalisation des cxcr-4/sdf-1 à l'aide d'inhibiteurs de kinase x de moelle osseuse
CN105085474B (zh) 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
TW201607930A (zh) * 2014-07-18 2016-03-01 百濟神州有限公司 作為ｔ７９０ｍ／ｗｔ－ｅｇｆｒ的選擇性和不可逆的激酶抑制劑的５－氨基－４－氨甲醯基－吡唑化合物及其用途
WO2016019237A2 (fr) * 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
EP3233103B1 (fr) 2014-12-18 2020-10-14 Principia Biopharma Inc. Traitement de le pemphigus
WO2016192074A1 (fr) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Inhibiteurs de la btk
WO2016210165A1 (fr) 2015-06-24 2016-12-29 Principia Biopharma Inc. Inhibiteurs de la tyrosine kinase
KR20180109842A (ko) 2015-09-16 2018-10-08 록쏘 온콜로지, 인코포레이티드 화합물
RS64908B1 (sr) * 2015-11-17 2023-12-29 Merck Patent Gmbh Metode za lečenje multiple skleroze korišćenjem jedinjenja pirimidina i piridina sa inhibitornom aktivnošću btk
CA3008488C (fr) * 2015-12-16 2023-10-10 Loxo Oncology, Inc. Composes utilises comme inhibiteurs de kinase
TWI726017B (zh) 2015-12-16 2021-05-01 德商百靈佳殷格翰國際股份有限公司 做為布魯頓式酪胺酸激酶（ｂｔｋ）抑制劑之雜芳族化合物
US10570118B2 (en) 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
EP3433246B1 (fr) 2016-03-24 2022-05-04 Mission Therapeutics Limited Dérivés de 1-cyano-pyrrolidine comme des inhibiteurs de dbu
CN107382973B (zh) * 2016-05-16 2020-08-07 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺衍生物及其制备方法和药物组合物
CN115054586A (zh) 2016-06-29 2022-09-16 普林斯匹亚生物制药公司 改性的释放制剂
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
CN111148743B (zh) 2017-10-06 2023-12-15 福马治疗有限公司 抑制泛素特异性肽酶30
WO2019091441A1 (fr) * 2017-11-10 2019-05-16 苏州信诺维医药科技有限公司 Composé 5-amino pyrazole carboxamide en tant qu'inhibiteur de btk et son procédé de préparation
CN111225669B (zh) * 2017-11-10 2020-12-29 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的晶型i
CN111212644B (zh) * 2017-11-10 2021-01-15 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体
CN108530436B (zh) * 2018-05-17 2020-12-29 黄传满 一种吡唑类化合物及其制备方法和应用
EP3860989B1 (fr) 2018-10-05 2023-04-05 Forma Therapeutics, Inc. Pyrrolines fusionnées qui agissent en tant qu'inhibiteurs de la protéase 30 (usp30) spécifique de l'ubiquitine
WO2020188015A1 (fr) 2019-03-21 2020-09-24 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
EP3972956A1 (fr) * 2019-05-21 2022-03-30 Janssen Pharmaceutica NV Procédés et intermédiaires pour préparer un inhibiteur de btk
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
TWI809489B (zh) * 2020-09-10 2023-07-21 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
WO2022140246A1 (fr) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Procédés et composés destinés à l'autophagie ciblée
CN115611810A (zh) * 2021-07-16 2023-01-17 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
WO2023150663A1 (fr) * 2022-02-04 2023-08-10 Retune Pharma Inc. Entités chimiques, compositions et méthodes

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
AU2002366440A1 (en) * 2001-09-27 2003-09-09 Smithkline Beecham Corporation Chemical compounds
ATE534632T1 (de) * 2006-04-11 2011-12-15 Vertex Pharma Thiazole, imidazole und pyrazole als proteinkinasehemmer
NZ601278A (en) 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
AU2008276521B2 (en) * 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
US20110224235A1 (en) * 2008-07-16 2011-09-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US8541575B2 (en) 2008-07-24 2013-09-24 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
TWI557127B (zh) * 2009-09-04 2016-11-11 百健Ｍａ公司 布魯頓氏酪胺酸激酶抑制劑
EP2582668B1 (fr) * 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Composes carboline carboxamide utiles en tant qu'inhibiteurs de kinase
EP2882741B1 (fr) * 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN106132507A (zh) 2014-04-09 2016-11-16 唐纳森公司 自承式折叠的片材材料以及过滤元件
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
CA2888960C (fr) 2017-08-15
ES2625944T3 (es) 2017-07-21
CO7350624A2 (es) 2015-08-10
JP2015535277A (ja) 2015-12-10
MX2015005422A (es) 2015-08-05
BR112015009624A2 (pt) 2017-11-14
US20150291554A1 (en) 2015-10-15
CL2015001168A1 (es) 2015-07-10
PE20151070A1 (es) 2015-08-01
US10815213B2 (en) 2020-10-27
IL238571A0 (en) 2015-06-30
WO2014068527A1 (fr) 2014-05-08
EP2914586B1 (fr) 2017-04-05
TW201431851A (zh) 2014-08-16
TWI518080B (zh) 2016-01-21
AP2015008381A0 (en) 2015-04-30
US20170283393A1 (en) 2017-10-05
EP2914586A1 (fr) 2015-09-09
US20210002251A1 (en) 2021-01-07
KR20150075114A (ko) 2015-07-02
DOP2015000100A (es) 2015-12-31
KR101668574B1 (ko) 2016-10-24
JP6178861B2 (ja) 2017-08-09
US20190202798A1 (en) 2019-07-04
AU2013340345B2 (en) 2016-10-27
PH12015500940A1 (en) 2015-06-29
EA201500393A1 (ru) 2016-05-31
CR20150228A (es) 2015-09-14
CN105008344A (zh) 2015-10-28
NI201500059A (es) 2015-06-05
GEP201606597B (en) 2017-01-10
CN105008344B (zh) 2017-07-25
MD20150035A2 (ro) 2015-10-31
US10266513B2 (en) 2019-04-23
AU2013340345A1 (en) 2015-04-30
SG11201502893WA (en) 2015-05-28
CA2888960A1 (fr) 2014-05-08
HK1211293A1 (en) 2016-05-20

Similar Documents

Publication Publication Date Title
TN2015000168A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
MA38961A1 (fr) Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
LTPA2016034I1 (lt) Brutono tirozinkinazės inhibitoriai
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MA44674A (fr) Inhibiteurs de bromodomaine
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
MA38391B1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA38190A2 (fr) Inhibiteurs d'autotaxine
FR3034993B1 (fr) Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA34815B1 (fr) Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib
MA38056B1 (fr) Inhibiteurs de la tyrosine kinase de bruton
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses